Brief: Coherus Oncology Inc - Announces Agreement With Janssen - SEC Filing
04/02/2026 13:44
Feb 4 (Reuters) - Coherus Oncology Inc CHRS.O: COHERUS ONCOLOGY INC - ANNOUNCES AGREEMENT WITH JANSSEN - SEC FILING COHERUS ONCOLOGY INC: JANSSEN WILL PROVIDE PASRITAMIG TO COMPANY, WHO WILL BE SPONSOR OF PHASE 1B CLINICAL TRIAL COHERUS ONCOLOGY INC - JANSSEN AND CO EACH RETAIN ALL COMMERCIAL RIGHTS TO THEIR RESPECTIVE COMPOUNDS Source text: [ID:n0001104659-26-010065] Further company coverage: CHRS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coherus Oncology
See all newsBrief: Coherus Oncology Initiates Process To Sell Legacy Biosim Assets
Brief: Coherus Oncology Announces Special Dividend Of Biosimilar Contingent Value Rights
Coherus Oncology Inc reports results for the quarter ended June 30 - Earnings Summary
Coherus Oncology Q2 revenue rises 40% on higher LOQTORZI volume, but slightly falls below estimates
Brief: Coherus Oncology Q2 Net Income USD -20.631 Million